Search results
Lab-made universal blood could revolutionize transfusions. Scientists just got one step closer to...
Live Science via Yahoo News· 6 days agoThe mucus in our gut does. So, we simply borrowed the enzymes from the bacteria that normally...
Colorectal cancer to be topic of discussion at event in east Gainesville
The Gainesville Sun via Yahoo News· 6 days agoThe keynote speakers will be Dr. Leighton Elliott, a UF chief hematology and oncology fellow who...
The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs
Zacks via Yahoo Finance· 3 days agoBest-Performing Stocks Amgen is one of the biggest biotech companies in the world, with a strong...
Sobi’s Aspaveli obtains indication extension approval in Europe
Pharmaceutical Technology via Yahoo Finance· 7 days agoSobi has received approval for an indication extension from the European Commission for Aspaveli to...
2,145 Shares in Novartis AG (NYSE:NVS) Bought by Wealthcare Advisory Partners LLC
ETF DAILY NEWS· 5 days agoWealthcare Advisory Partners LLC bought a new stake in Novartis AG (NYSE:NVS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities ...
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 6 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
AncestryDNA, 23andMe introduce you to new relatives. Now the nightmare: They won't offer medical...
USA TODAY via Yahoo News· 7 days ago"Like, we're not trying to take money. I don't know what their thoughts were, but they didn't want...
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in...
Digital Journal· 1 day agoFirst data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.Further updates from the IV arm; a fifth CR has been observed, ...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
FOX 4 Kansas City· 1 day agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 hours agoBOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson